Stock EVAX EVAXION BIOTECH A/S
Add to a list
To use this feature you must be a member
Log inSign up

Evaxion Biotech A/S

Equities

EVAX

US29970R2040

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
4.11 USD +1.73% Intraday chart for Evaxion Biotech A/S +3.01% -40.06%
Apr. 17 Evaxion Announces Phase 2 Clinical Trial Update CI
Apr. 11 European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Evaxion Biotech A/S

Evaxion Announces Phase 2 Clinical Trial Update CI
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading MT
Certain Warrants of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain American Depositary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain Ordinary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
ADRs End Lower; Meta Data Slides 22% DJ
Sector Update: Health Care Stocks Slide Late Afternoon MT
Sector Update: Health Care Stocks Slipping in Afternoon Trading MT
Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies; Shares Jump MT
Ladenburg Thalmann Upgrades Evaxion Biotech to Buy From Neutral, Price Target is $8 MT
Transcript : Evaxion Biotech A/S, 2023 Earnings Call, Apr 02, 2024
Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection CI
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
Evaxion Biotech A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
Transcript : Evaxion Biotech A/S - Special Call
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT

Chart Evaxion Biotech A/S

Chart Evaxion Biotech A/S
More charts

Company Profile

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Sector
Biotechnology & Medical Research
Calendar
2024-05-08 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.11 USD
Average target price
11.75 USD
Spread / Average Target
+185.89%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EVAXION BIOTECH A/S Stock Evaxion Biotech A/S
-40.06% 21.43M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.78% 41.36B
LONZA GROUP AG Stock Lonza Group AG
+44.81% 41.3B
MODERNA, INC. Stock Moderna, Inc.
+4.01% 39.61B
CELLTRION, INC. Stock Celltrion, Inc.
-15.14% 25.62B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.16% 24.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.08% 18.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.67% 11.82B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+24.76% 11.85B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.01% 11.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EVAX Stock
  4. News Evaxion Biotech A/S
  5. Evaxion Biotech Says CEO Resigns, Per Norlen Named as Replacement; Shares Drop